- Investing Ideas
- Belgian Pharmaceuticals & Biotech Healthy potentially undervalued
Belgian Pharmaceuticals & Biotech Healthy potentially undervalued
Results
2
0 new
Companies which are potentially undervalued and in an acceptable financial position.
2 companies
UCB
Market Cap: €48.0b
A biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide.
UCB
€252.00
7D
2.2%
1Y
53.3%
argenx
Market Cap: €37.7b
A commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally.
ARGX
€607.40
7D
3.9%
1Y
10.0%